Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.595 USD | +1.59% | -4.27% | +11.35% |
15/03 | RBC Cuts Price Target on aTyr Pharma to $16 From $19, Keeps Outperform Rating, Speculative Risk Qualifier | MT |
14/03 | Transcript : ATyr Pharma, Inc., Q4 2023 Earnings Call, Mar 14, 2024 |
Sales 2024 * | 2.62M 219M | Sales 2025 * | 9.26M 772M | Capitalization | 107M 8.9B |
---|---|---|---|---|---|
Net income 2024 * | -63M -5.26B | Net income 2025 * | -66M -5.51B | EV / Sales 2024 * | 40.6 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 11.5 x |
P/E ratio 2024 * |
-1.58
x | P/E ratio 2025 * |
-1.64
x | Employees | 58 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.38% |
Latest transcript on aTyr Pharma, Inc.
1 day | +1.59% | ||
1 week | -4.27% | ||
Current month | -19.49% | ||
1 month | -17.80% | ||
3 months | -3.09% | ||
6 months | +25.60% | ||
Current year | +11.35% |
Managers | Title | Age | Since |
---|---|---|---|
Sanjay Shukla
CEO | Chief Executive Officer | 52 | 30/16/30 |
Jill Broadfoot
DFI | Director of Finance/CFO | 63 | 30/18/30 |
Lisa Carey
CTO | Chief Tech/Sci/R&D Officer | - | 01/15/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Paul Schimmel
FOU | Founder | 83 | 08/05/08 |
Tim Coughlin
CHM | Chairman | 57 | 10/17/10 |
John Clarke
BRD | Director/Board Member | 70 | 01/05/01 |
Date | Price | Change | Volume |
---|---|---|---|
29/24/29 | 1.57 | 0.00% | 36 043 |
26/24/26 | 1.57 | -1.57% | 239,955 |
25/24/25 | 1.595 | -0.31% | 306,541 |
24/24/24 | 1.6 | -1.23% | 288,059 |
23/24/23 | 1.62 | -1.22% | 238,347 |
Delayed Quote Nasdaq, April 29, 2024 at 07:22 pm IST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+11.35% | 107M | |
+2.21% | 42.75B | |
+47.70% | 41.61B | |
+11.32% | 41.34B | |
-12.36% | 26.59B | |
+7.90% | 25.49B | |
-23.72% | 18.12B | |
+29.58% | 12.24B | |
-1.99% | 11.76B | |
+7.88% | 11B |
- Stock Market
- Equities
- LIFE Stock